Real-life efficacy and safety of paritaprevir/ritonavir, ombitasvir, and dasabuvir in chronic hepatitis C patients in Hong Kong.

Autor: Chan HL; Department of Medicine and Therapeutics and Institute of Digestive Disease, The Chinese University of Hong Kong, Hong Kong., Tsang OT; Department of Medicine and Geriatrics, Princess Margaret Hospital, Hong Kong., Hui YT; Department of Medicine, Queen Elizabeth Hospital, Hong Kong., Fung J; Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong., Lui GC; Department of Medicine and Therapeutics and Institute of Digestive Disease, The Chinese University of Hong Kong, Hong Kong., Lai CL; Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong., Wong GL; Department of Medicine and Therapeutics and Institute of Digestive Disease, The Chinese University of Hong Kong, Hong Kong., Chan KH; Department of Medicine, North District Hospital, Hong Kong., But DY; Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong., Lai MS; Department of Medicine, North District Hospital, Hong Kong., Lao WC; Department of Medicine, Pamela Youde Nethersole Eastern Hospital, Hong Kong., Chan CK; Department of Medicine and Therapeutics and Institute of Digestive Disease, The Chinese University of Hong Kong, Hong Kong., Lam YS; Department of Medicine, Queen Elizabeth Hospital, Hong Kong., Seto WK; Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong., Li C; Department of Medicine, Queen Elizabeth Hospital, Hong Kong., Yuen MF; Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong., Wong VW; Department of Medicine and Therapeutics and Institute of Digestive Disease, The Chinese University of Hong Kong, Hong Kong.
Jazyk: angličtina
Zdroj: Journal of gastroenterology and hepatology [J Gastroenterol Hepatol] 2017 Jun; Vol. 32 (6), pp. 1230-1233.
DOI: 10.1111/jgh.13663
Abstrakt: Background and Aim: In registration studies, combination therapy of paritaprevir/ritonavir, ombitasvir, and dasabuvir (PrOD) with and without ribavirin for 12-24 weeks can achieve > 90% sustained virological response (SVR) for genotype 1 hepatitis C virus (HCV) infection. However, data in Asia is scanty. We aimed to study the efficacy and safety of this combination therapy in chronic hepatitis C patients in Hong Kong.
Methods: We retrospectively analyzed data from six local hospitals that have prescribed PrOD with and without ribavirin to patients with genotype 1 chronic HCV infection as part of a global compassionate program.
Results: Among 41 patients treated, 35 (85%) patients had genotype 1b HCV infection, 6 (15%) had co-infection with human immunodeficiency virus, 35 (85%) failed previous peginterferon and ribavirin therapy, 25 (61%) had compensated liver cirrhosis, and 3 (7%) had liver transplantation. Thirty-five (85%) patients received 12-week treatment and six patients received 24-week treatment; 26 (63%) patients received ribavirin combination. Thirty-nine (95%; 95% confidence interval 88.5-100%) patients had undetectable HCV RNA at 12-week post-treatment, that is, SVR. The two patients who did not develop SVR discontinued treatment prematurely; both of them were treatment experienced with liver cirrhosis complicated by acute renal failure unrelated to the treatment of PrOD and ribavirin. No patient had hepatic decompensation.
Conclusions: Paritaprevir/ritonavir, ombitasvir, and dasabuvir with or without ribavirin is effective and safe in patients with genotype 1 HCV infection in real-life clinical setting in Hong Kong.
(© 2016 Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd.)
Databáze: MEDLINE
Externí odkaz: